biostudies-literaturePlumb IDCenters for Disease Control and PreventionU.S. Department of Health and Human Services2596-2604https://www.ebi.ac.uk/biostudies/studies/S-EPMC9995303biostudies-literatureUnknown41(15)<h4>Background</h4>Monitoring the effectiveness of COVID-19 vaccines against SARS-CoV-2 infections remains important to inform public health responses. Estimation of vaccine effectiveness (VE) against serological evidence of SARS-CoV-2 infection might provide an alternative measure of the benefit of vaccination against infection.<h4>Methods</h4>We estimated mRNA COVID-19 vaccine effectiveness (VE) against development of SARS-CoV-2 anti-nucleocapsid antibodies in March-October 2021, during which the Delta variant became predominant. Participants were enrolled from four participating healthcare systems in the United States, and completed electronic surveys that included vaccination history. Dried blood spot specimens collected on a monthly basis were analyzed for anti-spike antibodies, and, VaccineEstimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.PMC9995303NC DHHS GTS #4992775D30120C08405Uschner DBerry AAEdelstein SLink-Gelles RWard JFeldstein LLarsen MPWeintraub WSFette LMRunyon MSSaydah SSantos RPTjaden AHFriedman-Klabanoff DAhmed AWierzba TFWard LMPlumb IDfalseEstimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.<h4>Background</h4>Monitoring the effectiveness of COVID-19 vaccines against SARS-CoV-2 infections remains important to inform public health responses. Estimation of vaccine effectiveness (VE) against serological evidence of SARS-CoV-2 infection might provide an alternative measure of the benefit of vaccination against infection.<h4>Methods</h4>We estimated mRNA COVID-19 vaccine effectiveness (VE) against development of SARS-CoV-2 anti-nucleocapsid antibodies in March-October 2021, during which the Delta variant became predominant. Participants were enrolled from four participating healthcare systems in the United States, and completed electronic surveys that included vaccination history. Dried blood spot specimens collected on a monthly basis were analyzed for anti-spike antibodies, and, 2023-01-01T00:00:00Z2023 Apr2025-04-22T18:16:06.603Z2025-02-19T01:12:40.687ZS-EPMC99953033693203110.1016/j.vaccine.2023.03.006